|
2023 Journal Article ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patientsAoude, Lauren G., Brosda, Sandra, Ng, Jessica, Lonie, James M., Belle, Clemence J., Patel, Kalpana, Koufariotis, Lambros T., Wood, Scott, Atkinson, Victoria, Smithers, B. Mark, Pearson, John V., Waddell, Nicola, Barbour, Andrew P. and Bonazzi, Vanessa F. (2023). ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients. Journal of Molecular Diagnostics, 25 (10), 771-781. doi: 10.1016/j.jmoldx.2023.06.014 |
|
2023 Journal Article Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaCass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M., Smith, J. L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G. ... Ferrajoli, A. (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34 (9), 796-805. doi: 10.1016/j.annonc.2023.06.007 |
|
2023 Journal Article Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in CombinationArance, Ana, de la Cruz-Merino, Luis, Petrella, Teresa M., Jamal, Rahima, Ny, Lars, Carneiro, Ana, Berrocal, Alfonso, Márquez-Rodas, Ivan, Spreafico, Anna, Atkinson, Victoria, Costa Svedman, Fernanda, Mant, Andrew, Khattak, Muhammad A., Mihalcioiu, Catalin, Jang, Sekwon, Cowey, C Lance, Smith, Alan D., Hawk, Natalyn, Chen, Ke, Diede, Scott J., Krepler, Clemens and Long, Georgina V. (2023). Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. Journal of Clinical Oncology, 41 (1), 75-85. doi: 10.1200/JCO.22.00221 |
|
2023 Journal Article Health-related quality of life in patients with melanoma brain metastases treated with immunotherapyThompson, Jake R., Lai-Kwon, Julia, Morton, Rachael L., Guminski, Alexander D., Gonzalez, Maria, Atkinson, Victoria, Sandhu, Shahneen, Brown, Michael P., Menzies, Alexander M., Mcarthur, Grant A., Lo, Serigne N., Long, Georgina V. and Bartula, Iris (2023). Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Immunotherapy, 15 (8), 593-610. doi: 10.2217/imt-2022-0262 |
|
2023 Journal Article Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemiaBurgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631 |
|
2023 Journal Article Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Weber, Jeffrey S., Schadendorf, Dirk, Del Vecchio, Michele, Larkin, James, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Brown, Michael P., Rutkowski, Piotr, Haydon, Andrew, Grob, Jean-Jacques, Schachter, Jacob, Queirolo, Paola, De La Cruz-Merino, Luis, Van Der Westhuizen, Andre, Menzies, Alexander M. ... Long, Georgina V. (2023). Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of Clinical Oncology, 41 (3), 517-527. doi: 10.1200/JCO.22.00533 |
|
2023 Journal Article Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapySandhu, Shahneen, Atkinson, Victoria, Cao, Maria González, Medina, Theresa, Rivas, Ainara Soria, Menzies, Alexander M., Caro, Ivor, Roberts, Louise, Song, Yuyao, Yan, Yibing, Guo, Yu, Xue, Cloris and Long, Georgina V. (2023). Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy. European Journal of Cancer, 178, 180-190. doi: 10.1016/j.ejca.2022.10.019 |
|
2023 Journal Article Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional surveyThompson, Jake R., Fu, Hong, Saw, Robyn P. M., Sherman, Kerry A., Beedle, Victoria, Atkinson, Victoria, Boyle, Frances, O’Sullivan, Niamh A., Martin, Linda K. and Bartula, Iris (2023). Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey. Quality of Life Research, 32 (12), 3531-3545. doi: 10.1007/s11136-023-03492-0 |
|
2023 Journal Article BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomesLee, Joanna, Ahmed, Tasnia, Maurichi, Andrea, Di Guardo, Lorenzo, Stagno, Anna M., Warburton, Lydia, Taylor, Amelia. M., Livingstone, Elisabeth, Rehman, Saba, Khattak, Adnan, Kahler, Katharina C., Vanella, Vito, Atkinson, Victoria, Millward, Michael, Schadendorf, Dirk, Johnson, Douglas B., Ascierto, Paolo A., Hauschild, Axel, Lo, Serigne N., Long, Georgina V., Menzies, Alexander M. and Carlino, Matteo S. (2023). BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. European Journal of Cancer, 179, 87-97. doi: 10.1016/j.ejca.2022.11.009 |
|
2022 Journal Article Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyDimitriou, F., Namikawa, K., Reijers, I. L.M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C. J., Zaman, F., Haydon, A., Carvajal, R. D., Hamid, O., Dummer, R., Hauschild, A. ... Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33 (9), 968-980. doi: 10.1016/j.annonc.2022.06.004 |
|
2022 Journal Article Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaLarkin, James, Weber, Jeffrey, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Marie, Middleton, Mark R., De la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A. and Mandalá, Mario (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European Journal of Cancer, 173, 285-296. doi: 10.1016/j.ejca.2022.06.041 |
|
2022 Journal Article In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case seriesSanjida, Saira, Betz-Stablein, Brigid, Atkinson, Victoria, Janda, Monika, Barsoum, Ramez, Edwards, Harrison Aljian, Chiu, Frank, Tran, My Co, Soyer, H. Peter and Schaider, Helmut (2022). In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case series. Cancers, 14 (11) 2801, 2801. doi: 10.3390/cancers14112801 |
|
2022 Journal Article Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant TherapyNg, Gary, Xu, Wen and Atkinson, Victoria (2022). Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. Current Oncology Reports, 24 (10), 1273-1280. doi: 10.1007/s11912-022-01288-y |
|
2022 Journal Article Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomesShanker, Mihir D., Garimall, Sidyarth, Gatt, Nick, Foley, Heath, Crowley, Samuel, Le Cornu, Emma, Muscat, Kendall, Soon, Wei, Atkinson, Victoria, Xu, Wen, Watkins, Trevor, Huo, Michael, Foote, Matthew C. and Pinkham, Mark B. (2022). Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of Medical Imaging and Radiation Oncology, 66 (4), 536-545. doi: 10.1111/1754-9485.13403 |
|
2022 Journal Article Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlusAtkinson, Victoria, Robert, Caroline, Grob, Jean J., Gogas, Helen, Dutriaux, Caroline, Demidov, Lev, Gupta, Avinash, Menzies, Alexander M., Ryll, Bettina, Miranda, Flora, Banerjee, Hiya, Lau, Mike and Del Vecchio, Michele (2022). Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. European Journal of Cancer, 163, 79-87. doi: 10.1016/j.ejca.2021.12.015 |
|
2022 Journal Article Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisGoldinger, Simone M., Buder-Bakhaya, Kristina, Lo, Serigne N., Forschner, Andrea, McKean, Meredith, Zimmer, Lisa, Khoo, Chloe, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth I., Ascierto, Paolo A., Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas B., Gesierich, Anja, Kölblinger, Peter, Bennannoune, Naima, Cohen, Justine V., Kähler, Katharina C., Wilson, Melissa A., Cebon, Jonathan, Atkinson, Victoria, Smith, Jessica L., Michielin, Olivier, Long, Georgina V., Hassel, Jessica C., Weide, Benjamin, Haydu, Lauren E. ... Menzies, Alexander M. (2022). Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 162, 22-33. doi: 10.1016/j.ejca.2021.11.022 |
|
2022 Journal Article BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian settingScolyer, Richard A., Atkinson, Victoria, Gyorki, David E., Lambie, Duncan, O'Toole, Sandra, Saw, Robyn P.M., Amanuel, Benhur, Angel, Christopher M., Button-Sloan, Alison E., Carlino, Matteo S., Ch'ng, Sydney, Colebatch, Andrew J., Daneshvar, Dariush, Pires da Silva, Inês, Dawson, Tamara, Ferguson, Peter M., Foster-Smith, Erwin, Fox, Stephen B., Gill, Anthony J., Gupta, Ruta, Henderson, Michael A., Hong, Angela M., Howle, Julie R., Jackett, Louise A., James, Craig, Lee, C. Soon, Lochhead, Alistair, Loh, Daphne, McArthur, Grant A. ... Long, Georgina V. (2022). BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 54 (1), 6-19. doi: 10.1016/j.pathol.2021.11.002 |
|
2021 Journal Article Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaEggermont, Alexander MM., Meshcheryakov, Andrey, Atkinson, Victoria, Blank, Christian U., Mandala, Mario, Long, Georgina V., Barrow, Catherine, Di Giacomo, Anna Maria, Fisher, Rosalie, Sandhu, Shahneen, Kudchadkar, Ragini, Ortiz Romero, Pablo Luis, Svane, Inge Marie, Larkin, James, Puig, Susana, Hersey, Peter, Quaglino, Pietro, Queirolo, Paola, Stroyakovskiy, Daniil, Bastholt, Lars, Mohr, Peter, Hernberg, Micaela, Chiarion-Sileni, Vanna, Strother, Matthew, Hauschild, Axel, Yamazaki, Naoya, van Akkooi, Alexander CJ., Lorigan, Paul, Krepler, Clemens ... Robert, Caroline (2021). Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 158, 156-168. doi: 10.1016/j.ejca.2021.09.023 |
|
2021 Journal Article 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM studyAscierto, Paolo A., Dreno, Brigitte, Larkin, James, Ribas, Antoni, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Hsu, Jessie, Jones, Surai, Li, Haocheng, McKenna, Edward, Voulgari, Athina and McArthur, Grant A. (2021). 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study. Clinical Cancer Research, 27 (19), 5225-5235. doi: 10.1158/1078-0432.CCR-21-0809 |
|
2021 Journal Article Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: a real‐world studyYu, Su‐Yeon, Mckavanagh, Dan, McPherson, Ian, Walpole, Euan, Atkinson, Victoria and Hollingworth, Samantha (2021). Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: a real‐world study. Pharmacoepidemiology and Drug Safety, 30 (10) pds.5248, 1371-1379. doi: 10.1002/pds.5248 |
